More Delay for Weekly Exenatide

(MedPage Today)– The FDA declined to accept the novel extended-release type of exenatide (Bydureon) pending further safety and also efficiency data, medication makers Amylin as well as Lilly revealed.

Shares
|ShareTweet
You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

You must be logged in to post a comment.